Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 207-216

  Wu, Hong ^a   Yao, Li ^a   Mei, Jiazhuan ^a   Li, Feng ^a  

^a ZHENGZHOU PEOPLE S HOSPITAL   (China)

Author keywords

liposome; Ovarian carcinoma; transferrin receptor; tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; LIPOSOME; PLATINUM DERIVATIVE; TAXANE; TAXOID; TRANSFERRIN RECEPTOR;

ANIMAL; BAGG ALBINO MOUSE; CARCINOMA; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MOUSE; OVARY TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CARCINOMA; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RECEPTORS, TRANSFERRIN; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923107562     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Shahzad MK, Shin YH. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett 2012; 18: 76-85.
2. Chao HT, Wang L. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of paclitaxel in epithelial ovarian cancer via PI3K/Akt pathway. Cancer Lett 2012; 2: 29-38.
3. Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intra peritoneal carboplatin and intra peritoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 54-8.
4. Despierre E, Lambrechts D. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol 2010; 117: 358-365.
5. Curtin JP, Blessing JA. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 2001; 19: 1275-1278.
6. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792-795.
7. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999; 17: 2676-2680.
8. Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 2005; 41: 589-595.
9. McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M, Siu LL. A phase II trial of docetaxel and cisplatin in patients with recurrent or metastaticnasopharyngeal carcinoma. Oral Oncol 2002; 38: 686-690.
10. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5: 3-6.
11. Liebmann J, Cook JA, Mitchell JB. Solvent for paclitaxel, and toxicity. Lancet 1993; 342: 14-28.
12. Bidros DS and Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neuroth-erapeutics 2009; 3: 539-546.
13. Pillai JJ, Thulasidasan AK, Anto RJ, Chithralekha DN, Narayanan A, Kumar GS. Folic acid conjugated cross-linked acrylic polymer (FA-CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells. J Nanobiotechnology 2014; 12: 25.
14. Qin Y, Chen H, Zhang Q, Wang X, Yuan W, Kuai R, Tang J, Zhang L, Zhang Z, Zhang Q, Liu J, He Q. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 2011; 420: 304-312.
15. Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, Fan L, Xi Z, Jiang X, Zhang Q. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Bio materials 2012; 33: 5115-5123.
16. Miyata S, Kawabata S, Hiramatsu R, Doi A, Ikeda N, Yamashita T, Kuroiwa T, Kasaoka S, Maruyama K, Miyatake S. Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. Neurosurgery 2011; 68: 1380-1387.
17. Du W, Fan Y, Zheng N, He B, Yuan L, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 2013; 34: 794-806.
18. Qin Y, Chen H, Yuan W, Kuai R, Zhang Q, Xie F, Zhang L, Zhang Z, Liu J, He Q. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 2011; 419: 85-95.
19. Yin Y, Wu X, Yang Z, Zhao J, Wang X, Zhang Q, Yuan M, Xie L, Liu H, He Q. The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm Res 2013; 30: 2050-2062.
20. Gao H, Yang Z, Cao S, Xiong Y, Zhang S, Pang Z, Jiang X. Tumor cells and neo-vasculature dual targeting delivery for glioblastoma treatment. Biomaterials 2014; 35: 2374-2382.
21. Huile G, Shuaiqi P, Zhi Y, Shijie C, Chen C, Xinguo J, Shun S, Zhiqing P, Yu H. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Bio-materials 2011; 32: 8669-8675.